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a b s t r a c t 
In this paper we investigate the extent to which variable porosity drug-eluting coatings can provide bet- 
ter control over drug release than coatings where the porosity is constant throughout. In particular, we 
aim to establish the potential beneﬁts of replacing a single-layer with a two-layer coating of identical 
total thickness and initial drug mass. In our study, what distinguishes the layers (other than their indi- 
vidual thickness and initial drug loading) is the underlying microstructure, and in particular the effective 
porosity and the tortuosity of the material. We consider the effect on the drug release proﬁle of varying 
the initial distribution of drug, the relative thickness of the layers and the relative resistance to diffusion 
offered by each layer’s composition. Our results indicate that the contrast in properties of the two layers 
can be used as a means of better controlling the release, and that the quantity of drug delivered in the 
early stages can be modulated by varying the distribution of drug across the layers. We conclude that mi- 
crostructural and loading differences between multi-layer variable porosity coatings can be used to tune 
the properties of the coating materials to obtain the desired drug release proﬁle for a given application. 
© 2017 The Author(s). Published by Elsevier Ltd on behalf of IPEM. 
This is an open access article under the CC BY license. ( http://creativecommons.org/licenses/by/4.0/ ) 
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(. Introduction 
The topic of drug delivery is a truly multi-disciplinary research
rea and has been attracting the interest of engineers, mathemati-
ians, chemists and life scientists for decades. In particular, con-
rolled drug delivery has received much attention, particularly con-
erning the design of tablets [1–3] and local drug delivery devices
uch as stents [4] , transdermal patches [5] , contact lenses [6] and
rthopaedic implants [7] ( Fig. 1 ). Controlled release of drug from
ach of these vehicles can in principle be obtained by varying sys-
em design parameters. Some of the most common include the de-
ice geometry and materials; the physico-chemical properties of
he drug and; the drug loading conﬁguration. In the case of ex-
erimental studies, it is often demonstrated that different drug re-
ease proﬁles can be obtained by either varying the experimental
onditions (e.g. in-vitro versus in-vivo) or physical delivery sys-
em properties, whilst in the case of mathematical and compu-
ational modelling, it is usual for a sensitivity analysis of the un-
erlying model parameters to be conducted, and release proﬁles
ubsequently simulated . Both approaches are useful and indeed can∗ Corresponding author. 
E-mail addresses: sean.mcginty@glasgow.ac.uk , mcgintygs@hotmail.com 
(S. McGinty), giuseppe.pontrelli@gmail.com (G. Pontrelli). 
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 http://creativecommons.org/licenses/by/4.0/ ) e complementary in the quest for device design optimisation. In
he case of tablets, there is a body of literature concerning multi-
ayer systems (see e.g. [1–3] ), where the individual layers contain
ither different drugs or chemicals, or contrasting material proper-
ies from which the same drug or chemical is released in a bi- or
ulti-modal fashion. However, the literature concerning drug re-
ease from multi-layer coatings is lacking somewhat, particularly in
elation to mathematical modelling (see [12] as a rare exception).
his will be the focus of the current manuscript. 
Much of the research concerned with drug-eluting medical de-
ices is focussed on developing sophisticated computational mod-
ls which accurately simulate drug release and the subsequent dis-
ribution in the biological environment. The complexity of these
odels is increasing, with more and more realistic features being
ccounted for, including accurate 3D geometrical representations
f the device and anatomical features; anisotropic and spatially-
arying drug transport properties within the body and; complex
eatures such as nonlinear binding reactions. If, on the one hand,
hese models are indeed necessary to accurately simulate drug
ransport within the device and in the biological environment, on
he other hand it is clear that device manufacturers cannot inter-
ene on the underlying biology. What they can control, however,
re the properties of the device platform to ensure an optimal re-
ease [13] . Therefore, in this paper, we take a step back from theopen access article under the CC BY license. 
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Fig. 1. Examples of drug-delivery devices for different applications. From left to 
right: an orthopaedic implant [8] , a coronary stent [9] , a transdermal patch [10] and 
multi-layer tablets [11] . 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2. Example of two adjacent polymer coatings with different microstructural 
properties. These were prepared from different concentrations of polymer solutions 
(0.6% left and 0.8% right) [15] . 
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Fig. 3. Schematic showing a simpliﬁed one-dimensional conﬁguration of drug re- 
lease from a medical device coating into a release medium. Two porous layers of 
different thickness and structure are faced. Due to an initial difference of drug con- 
centrations between the two layers and the release medium, a mass ﬂux is es- 
tablished to the right and drug diffuses through the coating and into the release 
medium. Figure not to scale. fully coupled computational models (see e.g. [14] ) and focus in-
stead solely on the properties of the drug-containing coating. 
As a result of our focus on the coating, we consider only in-
vitro drug release, which excludes the biological environment. We
justify this as follows: ﬁrstly, it is routine for device manufacturers
to perform in-vitro drug release testing during the design stage to
establish the range of release proﬁles that can be obtained, and
to test the repeatability. This typically involves placing the drug-
eluting device in a test tube containing release medium and mea-
suring the mass of drug released under inﬁnite sink conditions.
Secondly, to incorporate equations for transport in a particular type
of tissue or speciﬁc biological environment (e.g. the arterial wall
in the case of drug-eluting stents [9,14,18,19] ) would be to detract
from the generality of the models. We therefore consider multi-
layer drug-eluting coatings generally, rather than focussing on a
particular device. 
The drug is typically contained within some durable/
biodegradable polymeric coating attached to the device plat-
form or embedded within a nanoporous structure. The drug
release proﬁle depends on a number of factors including the
porosity of the coating or bulk structure; the drug loading and ini-
tial distribution; the physico-chemical properties of the drug (e.g.
molecule size, solubility, etc.) and; the release medium. A certain
level of control is required: an excessive amount of drug delivered
too quickly can result in toxicity, but, on the other hand, the
therapeutic action vanishes when the drug concentration drops
below a given threshold. However, the most desirable release
proﬁle is not always known and may in fact be patient-speciﬁc
and therapy-dependent. 
Motivated by today’s advances in material fabrication and by
the increased capabilities of the miniaturisation of structures of-
fered by micro and nanotechnology, we propose variable porosity
multi-layer coatings as an additional means of controlling the drug
delivery and tailoring the release proﬁle to the desired application.
Our initial goal is to gain a better understanding of the potential
beneﬁts of replacing a single-layer with a two-layer drug-eluting
coating of identical total thickness and initial drug mass. In our
study, what distinguishes the layers (other than their thickness and
initial drug loading) is the underlying microstructure, and in par-
ticular the effective porosity and tortuosity of the material ( Fig. 2 ).
The primary novelty of our work is that whilst some existing drug
delivery devices already make use of bi- and multi-layer coatings,
to the best of our knowledge, no groups have theoretically inves-
tigated and assessed the effect on drug transport of varying the
porosity and material microstructure between layers. We are notware of any published experimental work which investigates drug
elease from variable porosity multi-layer coatings: we believe that
ur model may inspire and guide such experiments, which in turn
ould then be used to assess the predictive capacity of the model. 
The structure of the paper is as follows. In Section 2 we pro-
ide the mathematical formulation of the problem and deﬁne a
uitable non-dimensionalisation. We then propose, in Section 3 ,
 semi-analytical solution method which makes use of separation
f variables and expresses the solution as a Fourier series. A spe-
ial case which admits an analytical solution is also presented. In
he penultimate section we provide our results and investigate the
ensitivity of the release proﬁle to variations in the model parame-
ers. Finally, in Section 5 , we provide the conclusions of our study. 
. Mathematical formulation 
A drug delivery device typically includes a polymeric matrix
oating containing drug which is in contact with some release
edium. The particular geometry of the device varies between ap-
lications, but the drug-eluting coating can usually reasonably be
dealised as a slab ( layer ) of some thickness L . In Fig. 2 we display
n example of the situation we wish to model in the present work:
wo adjacent coating layers with different microstructural proper-
ies. Since the total thickness of drug-eluting coatings is typically
mall relative to the lateral coating dimensions, and the net drug
ransport is along a single direction, we restrict our attention to a
ne-dimensional model ( Fig. 3 ). The one-dimensional assumption
S. McGinty et al. / Medical Engineering and Physics 45 (2017) 51–60 53 
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Xs further justiﬁed by our focus on drug-release in-vitro, where the
edical implant is surrounded by homogeneous and isotropic re-
ease medium. We consider layers 1 and 2 to have thickness L 1 and
 2 , respectively, with L = L 1 + L 2 the total coating thickness, which
e keep ﬁxed in the following. We represent each layer of the
orous coating as a homogeneous material and deﬁne some rep-
esentative elementary volume (r.e.v.) of size larger than the pore
cale, but smaller than the typical length scale of the phenomenon.
ithin the r.e.v., we have solid and void parts. We choose to deﬁne
ll concentrations as intrinsically averaged variables, that is, aver-
ged with respect to the void volume, rather than the total r.e.v. 
Let c 1 and c 2 then denote the intrinsic concentrations of drug
n layer 1 of constant porosity φ1 and layer 2 of constant porosity
2 , respectively. We further deﬁne φ
e 
i 
, i = 1 , 2 ( 0 < φe 
i 
≤ φi ) as the
ffective transport-through porosities, which may be smaller than
he overall porosity of each layer if, for example, there are small
naccessible pores or dead-end pores [16] . Additionally, we directly
ccount for the fact that the molecules may have to travel through
n increased path length due to the circuitous nature of the pores
y introducing a tortuosity parameter τi , i = 1 , 2 . Assuming that
he coating is rapidly wetted and that the drugs are readily sol-
ble, it can be shown that drug transport satisﬁes the following
iffusion equations 
1 
∂c 1 
∂t 
= D e 1 
∂ 2 c 1 
∂x 2 
, −L 1 < x < 0 , t > 0 , (2.1) 
2 
∂c 2 
∂t 
= D e 2 
∂ 2 c 2 
∂x 2 
, 0 < x < L 2 , t > 0 , (2.2) 
here D e 1 = 
φe 
1 
D w 
τ1 
and D e 2 = 
φe 
2 
D w 
τ2 
are the effective diffusion co-
ﬃcients in each layer and D w is the corresponding free diffusion
f drug in water [17] . We emphasize that D w is independent of
he microstructure and that we consider only the case of the same
rug in each layer. In this work we envisage medical implant coat-
ngs which release drug through ﬂuid-ﬁlled pores only . As a conse-
uence, we do not consider diffusion in the solid phase, which can
e several orders of magnitude slower than in the liquid phase. 
For the sake of generality, we impose a mixed-type condition at
oth ends: 
D e 1 
∂c 1 
∂x 
= K 1 c 1 , x = −L 1 , t > 0 , (2.3) 
D e 2 
∂c 2 
∂x 
= K 2 c 2 , x = L 2 , t > 0 , (2.4) 
here we may, in principle, choose K 1 and K 2 to match experi-
entally measured ﬂux. The above boundary conditions allow us
o explore the two extreme cases of zero ﬂux and inﬁnite sink con-
itions (see Section 4 ). If, for example, the coating is attached to
n impermeable device (e.g. a stent) and drug release is measured
nder inﬁnite sink conditions, we can let K 1 = 0 and K 2 → ∞ . 
At the interface between the two layers we impose continuity
f ﬂux. To keep the problem general, this ﬂux accounts for a pos-
ible drug partitioning or a non-perfect contact, modelled through
 mass transfer coeﬃcient P ( m / s ): 
D e 1 
∂c 1 
∂x 
= P (c 1 − c 2 ) , x = 0 , t > 0 , (2.5) 
D e 1 
∂c 1 
∂x 
= −D e 2 
∂c 2 
∂x 
, x = 0 , t > 0 . (2.6) 
e assume that initially the drug is loaded at uniform concentra-
ions c 0 
1 
and c 0 
2 
in layers 1 and 2, respectively: 
 1 = c 0 1 , −L 1 ≤ x ≤ 0 , t = 0 , 
 2 = c 0 2 , 0 < x ≤ L 2 , t = 0 . (2.7) 
he case of a single layer can easily be recovered, as will be
emonstrated in Section 4 . .1. Non-dimensionalisation 
We now proceed to non-dimensionalise Eqs. (2.1) –(2.7) . We
hoose 
 
′ = x/L, t ′ = D e 1 t/φ1 L 2 , c ′ 1 = c 1 /c 0 1 , c ′ 2 = c 2 /c 0 1 . 
he non-dimensionalised equations (after dropping primes) are
hen: 
∂c 1 
∂t 
= ∂ 
2 c 1 
∂x 2 
, −δ < x < 0 , t > 0 , (2.8) 
∂c 2 
∂t 
= χ
φ
∂ 2 c 2 
∂x 2 
, 0 < x < 1 − δ, t > 0 , (2.9) 
∂c 1 
∂x 
= 1 c 1 , x = −δ, t > 0 , (2.10) 
∂c 1 
∂x 
= (c 1 − c 2 ) , x = 0 , t > 0 , (2.11) 
∂c 1 
∂x 
= χ ∂c 2 
∂x 
, x = 0 , t > 0 , (2.12) 
χ
∂c 2 
∂x 
= 2 c 2 , x = 1 − δ, t > 0 , (2.13) 
 1 = 1 , −δ ≤ x ≤ 0 , t = 0 . 
 2 = C 0 , 0 < x ≤ 1 − δ, t = 0 . (2.14) 
here 
δ = L 1 
L 
, χ = D 
e 
2 
D e 
1 
, C 0 = c 
0 
2 
c 0 
1 
, φ = φ2 
φ1 
, 
= P L 
D e 
1 
, 1 = K 1 L 
D e 
1 
, 2 = K 2 L 
D e 
1 
. 
e note that the non-dimensional parameter χ contains all
he important microstructural parameters which inﬂuence drug
elease. 
. Solution procedure 
.1. Solution by separation of variables 
The model given by (2.8) –(2.14) is amenable to solution by sep-
ration of variables, an approach we have adopted in previous
ork considering two-layer and multi-layer problems [18,19] . We
et 
 1 (x, t) = X 1 (x ) G 1 (t) , c 2 (x, t) = X 2 (x ) G 2 (t) . (3.1)
qs. (2.8) and (2.9) give rise to the ordinary differential equations 
ODEs): 
G ′ 1 
G 1 
= −λ2 1 , 
φ
χ
G ′ 2 
G 2 
= −λ2 2 , (3.2) 
hich yield the solution: 
 1 (t) = exp ( −λ2 1 t ) , G 2 (t) = exp 
(
−χ
φ
λ2 2 t 
)
, (3.3)
nd the Sturm–Liouville eigenvalue system: 
 
′′ 
1 = −λ2 1 X 1 , −δ < x < 0 , (3.4) 
X ′ 1 = 1 X 1 , x = −δ, (3.5) 
 
′ 
1 = χX ′ 2 , x = 0 , (3.6) 
 
′′ 
2 = −λ2 2 X 2 , 0 < x < 1 − δ, (3.7) 
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l−χX ′ 2 = 2 X 2 , x = 1 − δ, (3.8)
−X ′ 1 = (X 1 − X 2 ) , x = 0 , (3.9)
obtained by setting G 1 = G 2 , which implies 
λ1 = 
√ 
χ
φ
λ2 . (3.10)
The general solution of the ODEs (3.4) and (3.7) is: 
X 1 (x ) = a 1 cos (λ1 x ) + b 1 sin (λ1 x ) , 
X 2 (x ) = a 2 cos (λ2 x ) + b 2 sin (λ2 x ) , (3.11)
where the eigenvalues λi ( i = 1 , 2 ) and the unknown coeﬃcients a i 
and b i may be computed by imposing the boundary and interface
conditions as follows. From Eqs. (3.5) and (3.8) , we have: 
a 1 (λ1 sin (λ1 δ) + 1 cos (λ1 δ)) 
+ b 1 (λ1 cos (λ1 δ) − 1 sin (λ1 δ)) = 0 , (3.12)
a 2 [ −χλ2 sin (λ2 (1 − δ)) + 2 cos (λ2 (1 − δ))] 
+ b 2 [ χλ2 cos (λ2 (1 − δ)) + 2 sin (λ2 (1 − δ))] = 0 . (3.13)
From the interface conditions (3.6) and (3.9) , it follows: 
b 1 λ1 = χ λ2 b 2 , (3.14)
−b 1 λ1 = (a 1 − a 2 ) . (3.15)
Eqs. (3.12) –(3.15) form a system of four homogeneous linear al-
gebraic equations in the four unknowns a 1 , b 1 , a 2 and b 2 . To ob-
tain a solution different from the trivial one (0, 0, 0, 0), it is neces-
sary that the determinant of the coeﬃcient matrix associated with
the above system is equal to zero, that is: 
ϕ(λ1 , λ2 ) = (λ1 sin (λ1 δ) + 1 cos (λ1 δ)) 
× [(χλ2 cos (λ2 (1 − δ)) + 2 sin (λ2 (1 − δ))) 
+ χλ2 (−χλ2 sin (λ2 (1 − δ)) + 2 cos (λ2 (1 − δ)))] 
−
√ 
χφ(λ1 cos (λ1 δ) − 1 sin (λ1 δ)) 
× (−χλ2 sin (λ2 (1 − δ)) + 2 cos (λ2 (1 − δ))) = 0 (3.16)
By replacing λ1 with λ2 through the relation (3.10) , if the above
transcendental equation (eigen condition) in λ2 is satisﬁed, the co-
eﬃcients may be taken as: 
a 2 = χλ2 + 2 tan (λ2 (1 − δ)) −2 + χλ2 tan (λ2 (1 − δ)) 
b 2 , (3.17)
a 1 = a 2 − χ

λ2 b 2 , (3.18)
b 1 = 
√ 
χ φ b 2 , (3.19)
where the multiplicative constant b 2 is arbitrary and its value de-
pends on the initial condition (see below). We note that ϕ depends
on the parameters , δ, χ , φ, 1 , 2 (but not C 
0 ) and has inﬁnitely
many roots (eigenvalues), which are real and distinct. 
For each eigenvalue couple (λ1 m , λ2 m ) , m = 0 , 1 , 2 , ..., satisfying
(3.16) , the constants a 1 m , b 1 m and a 2 m are obtained from (3.18),
(3.19) and (3.17) , respectively, and thus the corresponding eigen-
functions X 1 m and X 2 m deﬁned in (3.11) are computed as: 
X 1 m = b 2 m ˜  X 1 m = b 2 m 
[
˜ a1 m cos (λ1 m x ) + ˜  b 1 m sin (λ1 m x ) 
]
, (3.20)
X 2 m = b 2 m ˜  X 2 m = b 2 m [ ˜  a2 m cos (λ2 m x ) + sin (λ2 m x ) ] , (3.21)
where the tilde indicates a variable which has been scaled by b 2 m .
Furthermore, the corresponding time-variable functions G 1 m 
and G deﬁned by Eqs. (3.3) are computed as: 2 m  1 m = exp (−λ2 1 m t) , G 2 m = exp 
(
−χ
φ
λ2 2 m t 
)
. (3.22)
 G 1 m = G 2 m ). Finally, the complete solution of the problem is given
y a linear superposition of the fundamental solutions (3.1) in the
orm: 
 1 (x, t) = 
∞ ∑ 
m =1 
A m ˜  X 1 m (x ) exp (−λ2 1 m t) , 
 2 (x, t) = 
∞ ∑ 
m =1 
A m ˜  X 2 m (x ) exp 
(
−χ
φ
λ2 2 m t 
)
, (3.23)
here the arbitrary constants A m (= b 2 m ) are determined through
he initial conditions (2.14) . The damping factors exp (−λ2 
1 m 
t) and
xp (−χ
φ
λ2 
2 m 
t) , m = 1 , 2 , . . . , measure the attenuation of the vari-
us terms in summations (3.23) . Because of the fast exponential
onvergence, the series (3.23) will be truncated at a ﬁnite number
f terms, in accordance with the accuracy desired at the time of
nterest. Since max x | A m ˜  X im (x ) | < 1 for any i = 1 , 2 , m > 1, to reach
n accuracy of 10 −r , it is suﬃcient to consider a ﬁnite series sum-
ation up to the index j > 1 such that 
1 j > 
√ 
r ln 10 
t 
nd the series is truncated at the ﬁrst j terms. A value of j = 30 is
onsidered for all times in the simulations. 
.2. Application of the initial condition 
By evaluating (3.23) at t = 0 and multiplying it by ˜ X 1 n , ˜ X 2 n , after
ntegration we obtain: 
 0 
−δ
∑ 
A m ˜  X 1 m ˜  X 1 n dx = 
∫ 0 
−δ
˜ X 1 n dx, n = 1 , 2 , . . . , (3.24)
nd 
 1 −δ
0 
∑ 
A m ˜  X 2 m ˜  X 2 n dx = C 0 
∫ 1 −δ
0 
˜ X 2 n dx, n = 1 , 2 , . . . (3.25)
y combining Eqs. (3.24) and (3.25) and by using the orthogonality
roperty of ( X 1 m , X 2 m ) [19] : 
 m 
(∫ 0 
−δ
˜ X 2 1 m dx + φ
∫ 1 −δ
0 
˜ X 2 2 m dx 
)
= 
∫ 0 
−δ
˜ X 1 m dx + φC 0 
∫ 1 −δ
0 
˜ X 2 m dx, (3.26)
e have: 
 m = 
∫ 0 
−δ ˜ X 1 m dx + φC 0 
∫ 1 −δ
0 
˜ X 2 m dx ∫ 0 
−δ ˜ X 
2 
1 m 
dx + φ ∫ 1 −δ0 ˜ X 2 2 m dx 
. (3.27)
.3. Computing mass 
The total mass of drug at any time can be evaluated by inte-
rating the drug concentrations in each layer over their respective
patial domain. If we normalise the total mass by its initial value,
hen the non-dimensional total mass of drug in the coating is given
y 
(t) = 1 
δ + ( 1 − δ) φC 0 
[∫ 0 
−δ
c 1 ( x, t) dx + φ
∫ 1 −δ
0 
c 2 (x, t) dx 
]
. 
(3.28)
etting θ i represent the non-dimensional mass of drug in each
ayer as a fraction of the total mass, we then have: 
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Table 1 
Reference dimensional parameter values used in the baseline simulations. The two 
layers have the same physical parameters and unhindered transport between the 
layers, and so they are equivalent to one layer. ( ∗) In reality, we wish to impose K 2 , 
P → ∞ , however, for the purposes of the numerical simulations it was found that 
the value 10 10 was suﬃcient to represent this case. 
Parameter Value (layer 1 − layer 2) 
D e 
i 
( m 2 s −1 ) 5 . 10 −11 − 5 . 10 −11 
L i (m) 5 . 10 
−5 − 5 . 10 −5 
φ i 0 . 6 − 0 . 6 
K i 0 − 10 10 ( ∗) 
P( ms −1 ) 10 10 ( ∗) 
θ
θ
w  
e  
M  
r
 
p  
t  
Table 2 
Range of non-dimensional parameters simulated. In each Study, three values of 
δ(0.2, 0.5, 0.8) were used. λmin 1 is an indicator of the release time. 
Study χ C 0 φ λmin 1 (δ = 0 . 5) 
Baseline 1 1 1 1.57 
1 0.5 1 1 1.16 
2 1 1 2.03 
2 1 0 1 1.57 
1 5 1 1.57 
3 1 1 2/3 1.61 
1 1 3/2 1.50 
r  
e
θ
T  
d  
i  
t  
p  
s  
t
c
c
3
 
p  
t  
λ
c
T  
t  
b
F
c
v
t1 (t) = 1 
δ + ( 1 − δ) φC 0 
∫ 0 
−δ
c 1 (x, t) dx 
= 1 
δ + ( 1 − δ) φC 0 
∞ ∑ 
m =1 
A m 
×
(
a 1 m sin (λ1 m δ) + b 1 m cos (λ1 m δ) − b 1 m 
λ1 m 
)
× exp (−λ2 1 m t) , (3.29) 
2 (t) = φ
δ + ( 1 − δ) φC 0 
∫ 1 −δ
0 
c 2 (x, t) dx 
= φ
δ + ( 1 − δ) φC 0 
∞ ∑ 
m =1 
A m 
×
(
a 2 m sin (λ2 m (1 − δ)) − cos (λ2 m (1 − δ)) + 1 
λ2 m 
)
× exp 
(
−χ
φ
λ2 2 m t 
)
(3.30) 
here c i ( i = 1 , 2 ) are given by (3.23) . It is then straightforward to
valuate the total non-dimensional mass of drug in the coating as
 = θ1 + θ2 and the cumulative fraction of drug release, M frac (the
elease proﬁle ) as M f rac = 1 − ( θ1 + θ2 ) . 
The depletion of the drug in coating as a result of the release
rocess is governed by an exponential decay as in the above equa-
ions. The analytical solution indicates that a complete release isig. 4. Baseline case: the non-dimensional concentration proﬁles at three times and perce
ontact at the interface (  → ∞ ), the concentration curves results are insensitive to th
ary with δ, but the release curves (green) do not (right). (For interpretation of the refe
his article). eached only asymptotically and Eqs. (3.29) and (3.30) allow one to
stimate the release time T r , within a given tolerance , through: 
1 (T r ) + θ2 (T r ) ≤ . 
he smallest eigenvalue λmin 1 = 
√ 
χ
φ
λmin 2 relates to the dominant
amping factor in the series (3.23), (3.29) and (3.30) . Compar-
ng λmin 
1 
between different parameter regimes provides an indica-
ion of the relative rate of release (see Table 2 ). For the particular
arameter regime of interest and a given initial mass per cross-
ectional area M 0 , the initial loading concentrations are calculated
hrough: 
 
0 
1 = 
M 0 
Lφ1 
(
δ + φC 0 ( 1 − δ) 
)
 
0 
2 = c 0 1 C 0 . (3.31) 
.4. Special case 
We note that in the special case where the microstructural
roperties of the layers are identical ( χ = φ = 1 ) then we can ob-
ain an analytical solution. In this case, the eigenvalues λ1 = λ2 =
, say, and are obtained by solving 
os ( λ) = 0 . 
he difference between the solutions c 1 and c 2 then arises only
hrough A m , which is calculated using the initial condition. It can
e shown that the solution in this case is ntage of drug mass released versus time (one layer, Table 1 ). Because of the perfect 
e location of the interface (left). The mass percentages in the individual layers do 
rences to colour in this ﬁgure legend, the reader is referred to the web version of 
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Fig. 5. Non-dimensional concentration proﬁles for three layer thickness ratios δ, with χ = 0 . 5 (left) and χ = 2 (right), and the other parameters as in Table 2 (Study 1). 
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Fig. 6. Comparison of release proﬁles at three values of χ (all the other values as 
in Table 2 and δ = 0 . 5 ). (For interpretation of the references to colour in this ﬁgure, 
the reader is referred to the web version of this article). (x, t) = 4 
π
∞ ∑ 
n =1 
( −1 ) n cos 
(
π(2 n −1)(x + δ) 
2 
){
(−1) n +1 sin 
(
π(2 n −1) δ
2 
)(
C 0
2 n − 1 
nd the release proﬁle is readily computed as: 
 f rac = 1 + 
8 
π2 
(
δ + (1 − δ) C 0 
) ∞ ∑ 
n =1 
{
(−1) n +1 sin 
(
π(2 n −1) δ
2 
)(
C 0 − 1
(2 n − 1
. Results and discussion 
In all simulations, we consider the typical boundary conditions
1 = 0 and 2 → ∞ . This situation is representative of the most
ommon in-vitro case where the coating is in contact with an im-
ermeable material (e.g. metal structure of the device) on one side
nd is exposed to an inﬁnite sink at the other side, where the drug
s washed away instantaneously. At the interface between the two
ayers, we choose  → ∞ to reﬂect ‘unhindered’ transport. 
The free diffusion coeﬃcient of molecules in liquids D w is typ-
cally of the order of 10 −9 m 2 s −1 [17] . By deﬁnition, 0 < φe 
i 
< 1 .
owever, extremely low ( φe 
i 
< 0 . 1 ) and extremely high ( φe 
i 
> 0 . 9 )
orosities would likely result in drug loading and mechanical con-
traints, respectively. A typical range of tortuosity values is 1 < τ i 
 6, although values as high as 10 have been reported [17] . Taken
ogether, we expect that the effect of the microstructure in each
ayer is to result in an effective diffusion coeﬃcient at most two or-
ers of magnitude smaller than the free diffusion coeﬃcient in wa-
er. We note that drug diffusion coeﬃcients in some polymers have
een reported to be as low as 10 −17 m 2 s −1 . However, it should be
oted that these are usually apparent diffusion coeﬃcients which
ikely incorporate other effects such as absorption and desorption
possibly in addition to the microstructure effects that we consider
ere). The effect of such processes can be to reduce the overall dif-
usion coeﬃcient by several orders of magnitude. In all simulations
e ﬁx D e 
1 
= 5 · 10 −11 and φ1 = 0 . 6 and consider the effects of vary-
ng the microstructure of each layer by varying φ and χ . 
Since the purpose of this study is to establish the beneﬁts of
eplacing a single layer with a two-layer coating of identical total
hickness L and initial drug mass, we ﬁx L = 10 −4 m in all simu-
ations. In reality, of course, the values of D e 
1 
, φ1 and L will vary
epending on the particular application. Since our focus is to in-
estigate the effect of the results on varying the ratio between the
arameters of each layer, we have decided to choose broadly typi-
al values, whilst acknowledging that this will not cover all cases.
he values we have chosen above, however, are representative of
mall hydrophobic compounds (e.g. sirolimus and paclitaxel) which
re typically coated on drug-eluting medical implants. In all of our
imulations the initial non-dimensional mass is 1. We choose not
o mathematically implement a ﬁxed dimensional mass. As a con-
equence, the initial dimensional loading concentrations c 0 
1 
and c 0 
2 
re to be back-calculated using (3.31) such that the desired initial
imensional mass is achieved. 
.1. Baseline model 
To assess the effect on drug release of variations in system pa-
ameters, we preliminarily assume that layer 1 and layer 2 have
dentical microstructural parameters ( χ = φ = 1 ) and equal initial
rug concentrations ( C 0 = 1 ): in this case we can use the analytical
olutions given by ( 3.32 ) and ( 3.33 ). The result is that our baseline
odel (see Table 1 ) essentially reduces to a single layer system
the solution is independent of the choice of δ). The resulting non-
imensional parameters are χ = φ = C 0 = 1 . −C 0 
}
exp 
(
−π2 ( 2 n −1 ) 2 t 
4 
)
, −δ < x < 1 − δ, (3.32) 
 
0 
}
exp 
(
−π2 ( 2 n −1 ) 2 t 
4 
)
. (3.33) 
In Fig. 4 we display the results of the baseline case, where each
ayer has identical initial drug loading and microstructure, so that
e effectively have a single layer. As a result of the inﬁnite sink
oundary condition at the release medium, drug is rapidly released
rom layer 2 in the early stages, whilst there is a small delay before
rug concentrations in layer 1 drop from their initial value. Drug
elease from layer 1 proceeds at a slower rate than in layer 2, and
herefore there is a difference in both the shape and the duration
f release in each layer. All of the drug has been released from the
ystem by approximately t = 3 (non-dimensional time). 
.2. Sensitivity analysis 
We are ultimately interested in quantifying the effect on drug
elease of having two separate layers (as opposed to a single layer)
ith different microstructure and drug loading parameters. There-
ore, it is of interest to vary the parameters, one at a time, around
he baseline values and to compare the resulting drug release pro-
les. We consider three cases (see Table 2 ): in Study 1 we assess
he effect of varying χ , whilst in Study 2 and Study 3 we vary C 0 
nd φ, respectively. In each case we consider three values of δ. 
tudy 1: effect of varying microstructure ratio χ
We now assess the effect of varying the relative microstruc-
ural parameters between the two layers. In Fig. 5 , left column, we
hoose χ such that the effective diffusion coeﬃcient in layer 2 is
alf that of layer 1, whilst in the right column the effective diffu-
ion coeﬃcient is 2 times greater. In the ﬁrst case we observe that
rug release from layer 1 is hindered by the lower effective diffu-
ion coeﬃcient in layer 2 and as a result there is a delay in drug
eing released from layer 1. Despite the lower effective diffusion
oeﬃcient in layer 2, there is still a burst release as a result of the
58 S. McGinty et al. / Medical Engineering and Physics 45 (2017) 51–60 
Fig. 7. Non-dimensional concentration proﬁles for three layer thickness ratios δ, with C 0 = 0 (left) and C 0 = 5 (right) and the other parameters as in Table 2 (Study 2). The 
dimensional values may be back-calculated from (3.31) . 
S. McGinty et al. / Medical Engineering and Physics 45 (2017) 51–60 59 
i  
c  
r  
b  
r  
l  
F  
b  
p  
t  
w  
i
 
t  
t  
l  
χ  
i  
t  
p  
p  
t  
p  
m
S
 
t  
c  
i  
l  
t  
i  
s  
d  
t  
m  
t  
b  
m  
t  
d  
I  
c
 
w  
b  
δ  
c  
s  
d  
o  
H  
s  
a  
t  
c  
l
S
 
f  
l  
a  
d  
Fig. 8. Comparison of release proﬁles at three values of C 0 (all the other values as 
in Table 2 and δ = 0 . 5 ). (For interpretation of the references to colour in this ﬁgure, 
the reader is referred to the web version of this article). 
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c  nﬁnite sink conditions, but this effect is smaller than the baseline
ase. In the second case, the faster effective diffusivity in layer 2
esults not only in signiﬁcantly faster drug release from layer 2,
ut also from layer 1 ( Fig. 5 , right). In Fig. 6 we plot the overall
elease proﬁles in these two cases and compare with the base-
ine (dashed red line). We display only the case of δ = 0 . 5 . From
ig. 6 we conclude that the parameter χ has a strong inﬂuence on
oth the shape (rate of release) and the duration of release. This is
erhaps unsurprising since χ appears prominently in the exponen-
ial damping factor (see (3.23) and (3.30) ). For χ = 0 . 5 and χ = 2
e observe faster release and slower release, respectively, as we
ncrease δ (not shown). 
The implication here is that, simply by varying the microstruc-
ure of the two layers, not only it is possible to alter the shape of
he release proﬁle, but it is also possible to ensure that drug is de-
ivered over some deﬁned period of time. We note that although
contains parameters relating to both the porosity and tortuos-
ty of each layer, it is the combination of these values (rather than
heir individual size) which deﬁnes the release proﬁle. For exam-
le, a value of χ = 2 could be obtained by doubling the effective
orosity of layer 2 (in comparison with layer 1) or, by doubling the
ortuosity of layer 1 (in comparison with layer 2). Therefore, this
arameter is highly important as it offers much ﬂexibility from the
anufacturing point of view. 
tudy 2: effect of varying ratio of initial concentrations C 0 
We now elucidate the effect of varying the initial drug concen-
ration between the two layers. In the ﬁrst case ( Fig. 7 , left) we
hoose the initial drug concentration in layer 2 to be zero, whilst
n the second case ( Fig. 7 , right) we choose the concentration in
ayer 2 to be ﬁve times that of layer 1. In the ﬁrst case we observe
hat layer 2 is initially rapidly inﬁltrated with drug, before drug
s subsequently released after it has traversed the thickness of the
econd layer. In the second case we observe that whilst layer 2 is
epleted rapidly as a result of the inﬁnite sink condition, at early
imes an increase in drug concentration (and consequently drug
ass) is observed in layer 1 due to the concentration gradient be-
ween the two layers (we are assuming that no drug can diffuse
etween the layers prior to the coating being placed in the release
edium). As layer 2 continues to be depleted of drug, eventually
he concentration gradient at the interface changes direction and
rug then diffuses from layer 1 into layer 2 before being released.
n each case, the value of δ has a signiﬁcant impact on the con-
entration proﬁle in each layer. 
In Fig. 8 we plot the overall release proﬁles in these two cases
ith δ = 0 . 5 and compare with the baseline (dashed red line). For
oth C 0 = 0 and C 0 = 5 we observe faster release as we increase
(not shown). We conclude that having a drug-free second layer
an delay the start of the drug-release process, which may be de-
irable in certain applications. In contrast, choosing a higher initial
rug concentration in the second layer can result in a larger burst
f drug which also may be advantageous in other circumstances.
owever, in all cases the overall duration of release results the
ame. Therefore, the non-dimensional parameter C 0 can be used
s a tuning parameter to vary the proportion of drug delivered in
he initial stages. The inﬂection point at t = 0 ( Fig. 8 , C 0 = 0 - black
urve) indicates a retardation time due to the ﬁlling of the second
ayer which is initially empty. 
tudy 3: effect of varying porosity ratio φ
By varying φ from 2/3 to 3/2, no signiﬁcant differences are
ound between the concentration proﬁles (not shown). The re-
ease proﬁles are virtually indistinguishable for high values of δ,
lthough minor differences in the proﬁles are observed as δ is re-
uced (not shown). These results reinforce the idea that it is theffective porosity in each layer φe 
i 
that drives the drug release,
ather than the overall porosity φi . 
Having studied separately the inﬂuence of the individual pa-
ameters, we note that a combination of the above cases should
e considered in order to meet the precise manufacturing require-
ents or with the aim of optimising some quantity. For example, if
he objective is to slow down the release, then it appears that the
imultaneous occurrence of the two cases χ < 1 , C 0 = 0 will boost
his property: in particular, a conﬁguration with a lower effective
orosity in layer 2 faced with one of higher effective porosity in
ayer 1 acts more favourably to achieve this goal: the time scale
or release from layer 2 is increased, and layer 1 acts as a reservoir
hat continuously supplies drug during elution. 
. Conclusions 
In this paper we have presented a mathematical model of drug
iffusion through two adjacent porous layers and we have carried
ut a systematic study of the effect on drug release of changes to
ystem parameters. Our results indicate that the contrast in proper-
ies of the two layers can be used as a means of better controlling
he release, and that the quantity of drug delivered in the early
tages can be modulated by varying the distribution of drug across
he layers. We conclude that microstructural and loading differ-
nces between variable porosity coating layers can be utilised to
une the properties of the coating materials to obtain the desired
rug release proﬁle for a given application. We expect that our re-
ults will generalise to the multi-layer case, with increasing num-
ers of layers exhibiting contrasting properties potentially provid-
ng additional ﬂexibility for targeting a speciﬁc release proﬁle. Fi-
ally, as we reduce the thickness of each layer, in the limit we can
btain a continuously changing porosity. Whilst we acknowledge
hat this may provide even more ﬂexibility in terms of controlling
he release, the model we consider is a useful starting point to as-
ess the effect of variable porosity. 
A number of implications arise from our work which are of
linical and industrial signiﬁcance. For example, in cases where the
linicians have in mind what the release proﬁle should be, then
ur model may in principle be used to infer the coating design pa-
ameters which will allow the device manufacturer to design the
oating which achieves this. In this way, our model may be used
60 S. McGinty et al. / Medical Engineering and Physics 45 (2017) 51–60 
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 as a tool in the design of the enhanced drug-eluting coatings of
the future. 
We would like to emphasise that we have made a number of
simpliﬁcations in this work. Perhaps the most signiﬁcant is the as-
sumption that drug is transported via a diffusive mechanism only.
Depending on the particular coating material under consideration,
it may be more appropriate to account for: polymer-drug interac-
tions; diffusion through the solid phase; erosion; swelling and/or
degradation. Additionally, in cases where ﬂuid penetration into the
coating is slow and/or the drug in question is poorly soluble, then
the model may need to account for the drug dissolution process.
Nevertheless, the approach we have presented here will be rele-
vant in a number of drug delivery cases and paves the way for the
future development of experiments which can inform the models.
Now that we have established that variable porosity coatings for
drug-eluting devices are worth further consideration, we will seek
to relax some of the above assumptions to consider more complex
systems in future work. 
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